Mundipharma, a proven global Pharmaceutical network, announces the seal of an exclusive sales agreement with Biosolution Co., Ltd, a Korea-based leader in manufacturing & distributing cell-based biotechnology, cell therapy products, human tissue models, and other related products, to market and distribute its fourth-generation autologous chondrocyte implantation product, CartiLife. Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife in South Korea.
“The Mundipharma story, spanning over six decades, is one that brings together a visionary approach and a pioneering spirit and is best told by patients, employees and the communities in which we serve,” says Raman Singh, CEO, Mundipharma. “Our dedication to putting patients at the heart of every business decision has ensured that we continue to grow and more importantly, improve the lives of the people who need our medicines the most,” he adds.

We are delighted to extend our relationship with Biosolution to include CartiLife, which adds to our portfolio of products for orthopedic care.

CartiLife is an autologous cartilage-derived chondrocyte cell therapy for the treatment of cartilage defects (ICRS grade 3 or 4). Its key benefits include significantly reduced risk of host-immune rejection due to its autologous nature, direct restoration of hyaline cartilage, and a less invasive surgery followed by shorter recovery times compared to alternative, comparable therapies.

Raman adds, "We are delighted to extend our relationship with Biosolution to include CartiLife, which adds to our portfolio of products for orthopedic care. It is also another example of our support for innovative treatments developed in Asia and our ability to increase their market presence," he adds.
This is the second deal between Mundipharma and Biosolution Co., Ltd following the exclusive sales agreement for the allogeneic keratinocyte cell therapy product, KeraHeal-Allo, which was announced in May 2016.